Woman and Man | 60 years and more
- | Country :
- France
- | organs :
- Leucémies aiguës
- | Specialty :
- Thérapies Ciblées
- Chimiothérapie
- Gériatrie
Extract
A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in patients aged ≥ 60 with newly diagnosed acute myeloid leukaemia (AML).
Scientific Abstract
en cours d'intégration;